Treatment or prevention method of radiation damage by administration of IL-5 receptor alpha chain binding antibody

A method for treating radiation damage associated with radiation exposure during radiation therapy of cancer in a patient, wherein the radiation therapy is radiation therapy for any cancer selected from the group consisting of small intestinal cancer, colorectal cancer, gastrointestinal stromal tumor (GIST), gastrointestinal carcinoid, gastric cancer, esophageal cancer, liver cancer, gallbladder/biliary cancer, pancreatic cancer, pancreatic/gastrointestinal neuroendocrine tumor, Langerhans cell histiocytosis, renal cell cancer, renal pelvic/ureteral cancer, adrenal tumor, osteosarcoma, soft tissue sarcoma, malignant lymphoma, bladder cancer, urethral cancer, prostate cancer, testicular tumor, penile cancer, endometrial cancer, cervical cancer, uterine tumor, ovarian tumor, female genital cancer, lung cancer, thymic tumor, mesothelioma, and breast cancer, wherein the method comprises administering an effective amount of an IL-5 receptor α chain binding antibody, wherein the IL-5 receptor α chain binding antibody or antibody-binding fragment thereof comprises:

• a heavy chain variable region comprising a complementary determining region 1 (HCDR1), a complementary determining region 2 (HCDR2) and a complementary determining region 1 (HCDR3) comprising the amino acid sequences SEQ ID NO:
• 1, SEQ ID NO:
• 2, and SEQ ID NO:
• 3, respectively;
• and
• a light chain variable region comprising a complementary determining region 1 (LCDR1), a complementary determining region 2 (LCDR2), and a complementary determining region 3 (LCDR3) comprising the amino acid sequences of SEQ ID NO:
• 4, SEQ ID NO:
• 5, and SEQ ID NO:
• 6, respectively.